Hemophilia A trial for people with FVIII inhibitors
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A and are male
- You have a history of FVIII inhibitor levels at or above 0.6 BU/mL
- You either tried immune tolerance induction (ITI) before or are currently doing ITI, possibly using Nuwiq, octanate, or wilate
- If you are doing ITI, you may also be on preventive medicines like emicizumab, aPCC, or rFVIIa
- You (or your parent/guardian) can sign consent and understand the study information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This study tests a new medicine called fitusiran to help prevent bleeding episodes in people with severe hemophilia A who are already receiving emicizumab. It may offer an additional treatment option for those with or without inhibitors.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.